Compare BHF & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | LIVN |
|---|---|---|
| Founded | 2016 | 1987 |
| Country | United States | United Kingdom |
| Employees | 1400 | N/A |
| Industry | Life Insurance | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | N/A | 2015 |
| Metric | BHF | LIVN |
|---|---|---|
| Price | $65.20 | $79.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $57.71 | ★ $72.43 |
| AVG Volume (30 Days) | 441.6K | ★ 698.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | N/A |
| Revenue This Year | $27.10 | $9.79 |
| Revenue Next Year | $1.09 | $6.63 |
| P/E Ratio | ★ $4.34 | $201.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $43.16 | $41.02 |
| 52 Week High | $66.80 | $85.27 |
| Indicator | BHF | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 47.75 |
| Support Level | $63.87 | $61.63 |
| Resistance Level | $65.36 | $80.96 |
| Average True Range (ATR) | 0.83 | 2.22 |
| MACD | -0.00 | -0.71 |
| Stochastic Oscillator | 55.70 | 16.94 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.